Medical Treatment Landscape for Active Acromegaly in A Pituitary Center in Israel
- 1 November 2020
- journal article
- research article
- Published by Elsevier BV in Endocrine Practice
- Vol. 26 (11), 1298-1303
- https://doi.org/10.4158/ep-2020-0171
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Signs and symptoms of acromegaly at diagnosis: the physician’s and the patient’s perspectives in the ACRO-POLIS studyEndocrine, 2018
- Acromegaly is associated with increased cancer risk: a survey in ItalyEndocrine-Related Cancer, 2017
- A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analoguesActa Endocrinologica, 2017
- Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III TrialJournal of Clinical Endocrinology & Metabolism, 2015
- Acromegaly: An Endocrine Society Clinical Practice GuidelineJournal of Clinical Endocrinology & Metabolism, 2014
- Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trialThe Lancet Diabetes & Endocrinology, 2014
- Estrogen treatment for acromegalyPituitary, 2012
- Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDYJournal of Clinical Endocrinology & Metabolism, 2012
- Place of Cabergoline in Acromegaly: A Meta-AnalysisJournal of Clinical Endocrinology & Metabolism, 2011
- Mortality in Patients with Pituitary DiseaseEndocrine Reviews, 2010